About: Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses
Creator	Zhang, Yan Shi, Wei Cao, Luyang Cao, Zhijian Chen, Yaoqing Li, Qiaoli Li, Wenxin Yan, Huimin Yang, Jingyi Zhou, Dihan Wu, Yingliang Hong, Wei Zhao, Zhenhuan
Source	Elsevier; Medline; PMC
abstract	Abstract Outbreaks of SARS-CoV, influenza A (H5N1, H1N1) and measles viruses in recent years have raised serious concerns about the measures available to control emerging and re-emerging infectious viral diseases. Effective antiviral agents are lacking that specifically target RNA viruses such as measles, SARS-CoV and influenza H5N1 viruses, and available vaccinations have demonstrated variable efficacy. Therefore, the development of novel antiviral agents is needed to close the vaccination gap and silence outbreaks. We previously indentified mucroporin, a cationic host defense peptide from scorpion venom, which can effectively inhibit standard bacteria. The optimized mucroporin-M1 can inhibit gram-positive bacteria at low concentrations and antibiotic-resistant pathogens. In this investigation, we further tested mucroporin and the optimized mucroporin-M1 for their antiviral activity. Surprisingly, we found that the antiviral activities of mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses were notably increased with an EC50 of 7.15μg/ml (3.52μM) and a CC50 of 70.46μg/ml (34.70μM) against measles virus, an EC50 of 14.46μg/ml (7.12μM) against SARS-CoV and an EC50 of 2.10μg/ml (1.03μM) against H5N1, while the original peptide mucroporin showed no antiviral activity against any of these three viruses. The inhibition model could be via a direct interaction with the virus envelope, thereby decreasing the infectivity of virus. This report provides evidence that host defense peptides from scorpion venom can be modified for antiviral activity by rational design and represents a practical approach for developing broad-spectrum antiviral agents, especially against RNA viruses.
has issue date	2011-07-31(xsd:dateTime)
bibo:doi	10.1016/j.peptides.2011.05.015
bibo:pmid	21620914
has license	els-covid
sha1sum (hex)	04493bf92e3c45eb1482e9abf869bd73cb2cdb40
schema:url	https://doi.org/10.1016/j.peptides.2011.05.015
resource representing a document's title	Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses
has PubMed Central identifier	PMC7115635
has PubMed identifier	21620914
schema:publication	Peptides
resource representing a document's body	covid:04493bf92e3c45eb1482e9abf869bd73cb2cdb40#body_text
is schema:about of	named entity 'measures' named entity 'activity' named entity 'scorpion venom' named entity 'host defense peptides' named entity 'inhibition' named entity 'represents' named entity 'measles' named entity 'HOST DEFENSE' named entity 'RNA VIRUSES' named entity 'ANTIVIRAL AGENTS' named entity 'COULD BE' named entity 'INCREASED' named entity 'YEARS' named entity 'PEPTIDES' named entity 'RAISED' named entity 'DEVELOPING' named entity 'DESIGN' named entity 'RESISTANT' named entity 'MODIFIED' named entity 'STANDARD' named entity 'DEMONSTRATED' named entity 'ANTIVIRAL ACTIVITY' named entity 'TO CONTROL' named entity 'VARIABLE' named entity 'VIRUSES' named entity 'SCORPION VENOM' named entity 'ORIGINAL' named entity 'SILENCE' named entity 'CONCERNS' named entity 'OUTBREAKS' named entity 'MEASLES' named entity 'SARS-COV' named entity 'REPORT' named entity 'INFLUENZA A' named entity 'H1N1' named entity 'APPROACH' named entity 'RECENT' named entity 'GRAM-POSITIVE BACTERIA' named entity 'VACCINATION' named entity 'DECREASING' named entity 'INFECTIVITY' named entity 'BACTERIA ' named entity 'PEPTIDE' named entity 'VIRUSES' named entity 'INFLUENZA' named entity 'VARIANT' named entity 'SCORPION VENOM' named entity 'INHIBITION' named entity 'MEASURES' named entity 'CONCENTRATIONS' named entity 'MEASLES' named entity 'H5N1' named entity 'TARGET' named entity 'BROAD' named entity 'PREVIOUSLY' named entity 'EVIDENCE' named entity 'H5N1' named entity 'PEPTIDE' named entity 'PATHOGENS' named entity 'EFFECTIVE' named entity 'TESTED' named entity 'DIRECT INTERACTION' named entity 'VIRAL DISEASES' named entity 'ANTIVIRAL' named entity 'LACKING' named entity 'VACCINATIONS' named entity 'ACTIVITY' named entity 'MEASLES VIRUS' named entity 'THEIR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software